Glycomacropeptide as an efficient agent to fight pathophysiological mechanisms of metabolic syndrome

Tools

Sauvé, Mathilde Foisy, Feldman, Francis, Sané, Alain Théophile, Koudoufio, Mireille, Patey, Natalie, Spahis, Schohraya, Butcher, James, Duan, Haonan, Figeys, Daniel, Marcil, Valérie, Stintzi, Alain and Levy, Emile (2024) Glycomacropeptide as an efficient agent to fight pathophysiological mechanisms of metabolic syndrome. Nutrients, 16 (6). ISSN 2072-6643

[thumbnail of Glycomacropeptide as an Efficient Agent to Fight Pathophysiological Mechanisms of Metabolic Syndrome]
Preview
 PDF (Glycomacropeptide as an Efficient Agent to Fight Pathophysiological Mechanisms of Metabolic Syndrome) - Published Version
Available under License Creative Commons Attribution.
Download (5MB) | Preview

Abstract

There is currently a growing interest in the use of nutraceuticals as a means of preventing the development of complex diseases. Given the considerable health potential of milk-derived peptides, the aim of this study was to investigate the protective effects of glycomacropeptide (GMP) on metabolic syndrome. Particular emphasis was placed on the potential mechanisms mitigating cardiometabolic disorders in high-fat, high-fructose diet-fed mice in the presence of GMP or Bipro, an isocaloric control. The administration of GMP for 12 weeks reduced obesity, hyperglycemia and hyperinsulinemia caused by a high-fat, high-fructose diet, resulting in a decline in insulin resistance. GMP also lessened systemic inflammation, as indicated by decreased circulating inflammatory cytokines. In the intestinal and hepatic tissues, GMP improved homeostasis by increasing insulin sensitivity and attenuating high-fat, high-fructose-induced inflammation, oxidative stress and endoplasmic reticulum stress. Biochemical and histological analyses revealed improved hepatic steatosis and fatty acid composition in the livers of high-fat, high-fructose diet-fed mice treated with GMP compared to Bipro. A trend toward a decrease in bile acids without any marked changes in intestinal microbiota composition characterized GMP-treated animals compared to those administered Bipro. GMP offers considerable potential for fighting metabolic syndrome-related components and complications given its beneficial effects on risk factors such as inflammation, oxidative stress and endoplasmic reticulum stress without involving the intestinal microbiota.

Item Type: Article
Uncontrolled Keywords: metabolism mice, inbred c57bl *caseins *peptide fragments endoplasmic reticulum stress fatty acids gut-liver axis inflammation metabolic syndrome milk peptide oxidative stress,metabolic syndrome,fatty acids,inflammation,milk peptide,gut–liver axis,endoplasmic reticulum stress,oxidative stress,food science,nutrition and dietetics,sdg 3 - good health and well-being ,/dk/atira/pure/subjectarea/asjc/1100/1106
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 02 Sep 2025 16:30
Last Modified: 08 Sep 2025 08:30
URI: https://ueaeprints.uea.ac.uk/id/eprint/100274
DOI: 10.3390/nu16060871

Downloads

Downloads per month over past year

Actions (login required)

View Item View Item